Comparison of the low dose short synacthen test (1 microg), the conventional dose short synacthen test (250 microg), and the insulin tolerance test for assessment of the hypothalamo-pituitary-adrenal axis in patients with pituitary disease.

Abdu TA, Elhadd TA, Neary R, Clayton RN

The Journal of clinical endocrinology and metabolism1 Mar 1999Cited by 198 (Europe PMC)

PMID10084558DOI10.1210/jcem.84.3.5535PepBankPUB-10084558

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone8

In this study, Cosyntropin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Cosyntropin.

01HumanNot a test of Cosyntropin aloneNon-randomized trialOther
In patients with pituitary disease, low-dose peak cortisol correlated with standard-dose cortisol at 30 min.
In plain wordsIn patients with pituitary disease, low-dose and standard-dose tetracosactrin results correlated.
Peptide
Cosyntropin
Outcome
Not applicableCorrelation between tetracosactrin protocols
Study
n = 64
Comparator
Standard-dose short synacthen test
Outcome group
Diagnostic test performance · Endocrine and hormones
Measurements
Correlation
0.85 r
LDSST versus SST
P
< 0.0001
correlation
Source sentences
Summary
and the LDSST peak cortisol response and the SST 30 min cortisol level (r = 0.85; P < 0.0001).
1 context sentence(design, population, supporting numbers)
Summary · context
We studied 64 patients with suspected or proven pituitary disease. All patients underwent SST and LDSST. Forty-two patients underwent ITT.
In this study, Cosyntropin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cosyntropin.
Report a problemFND-1008455803
02HumanNot a test of Cosyntropin aloneNon-randomized trialOther
In patients with pituitary disease, all but six reached maximal cortisol by 30 min during low-dose tetracosactrin testing.
In plain wordsIn patients with pituitary disease, all but six reached their highest cortisol by 30 min during low-dose tetracosactrin testing.
Peptide
Cosyntropin
Outcome
Not applicableTime to maximal cortisol response
Study
n = 64
Outcome group
Diagnostic test performance · Endocrine and hormones
Measurements
Patients without maximal cortisol response by 30 min
6 patients
low-dose test
Source sentences
Summary
In the LDSST, all but six patients achieved maximal cortisol response by 30 min.
1 context sentence(design, population, supporting numbers)
Summary · context
We studied 64 patients with suspected or proven pituitary disease. All patients underwent SST and LDSST. Forty-two patients underwent ITT.
In this study, Cosyntropin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cosyntropin.
Report a problemFND-1008455804
03HumanNot a test of Cosyntropin aloneNon-randomized trialOther
In patients with pituitary disease, low-dose tetracosactrin testing produced no falsely reassuring results.
In plain wordsIn patients with pituitary disease, low-dose tetracosactrin testing produced no falsely reassuring results.
Peptide
Cosyntropin
Outcome
Not applicableLow-dose falsely reassuring results
Study
n = 64
Outcome group
Diagnostic test performance · Endocrine and hormones
Source sentences
Summary
The sensitivity of the LDSST was 100% (cortisol response of >600 nmol/L indicates intact HPA axis), with no falsely reassuring results.
1 context sentence(design, population, supporting numbers)
Summary · context
We studied 64 patients with suspected or proven pituitary disease. All patients underwent SST and LDSST. Forty-two patients underwent ITT.
In this study, Cosyntropin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cosyntropin.
Report a problemFND-1008455807
04HumanNot a test of Cosyntropin aloneNon-randomized trialOther
In patients with pituitary disease, standard-dose tetracosactrin testing produced 2 of 64 falsely reassuring results and was less sensitive than low-dose testing.
In plain wordsIn patients with pituitary disease, standard-dose tetracosactrin testing was less sensitive than low-dose testing and gave falsely reassuring results.
Peptide
Cosyntropin
Outcome
IncreaseStandard-dose falsely reassuring results
Study
n = 64
Comparator
Low-dose short synacthen test
Outcome group
Diagnostic test performance · Endocrine and hormones
Measurements
Falsely reassuring results
2 patients
SST
Falsely reassuring proportion
3%
SST
Source sentences
Summary
SST (pass cortisol level, >600 nmol/L) was less sensitive than LDSST, it produced 2 of 64 (3%) falsely reassuring results.
1 context sentence(design, population, supporting numbers)
Summary · context
We studied 64 patients with suspected or proven pituitary disease. All patients underwent SST and LDSST. Forty-two patients underwent ITT.
In this study, Cosyntropin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cosyntropin.
Report a problemFND-1008455808
05HumanNot a test of Cosyntropin aloneNon-randomized trialOther
In patients with pituitary disease, low-dose tetracosactrin peak cortisol correlated with the insulin tolerance test response.
In plain wordsIn patients with pituitary disease, low-dose tetracosactrin results correlated with insulin tolerance test results.
Peptide
Cosyntropin
Outcome
Not applicableLow-dose test correlation with insulin tolerance test
Study
n = 42
Comparator
Insulin tolerance test
Outcome group
Diagnostic test performance · Endocrine and hormones
Measurements
Correlation
0.89 r
ITT versus LDSST
P
< 0.0001
correlation
Source sentences
Summary
There was a high correlation between the ITT and LDSST peak cortisol responses (r = 0.89; P < 0.0001),
1 context sentence(design, population, supporting numbers)
Summary · context
We studied 64 patients with suspected or proven pituitary disease. All patients underwent SST and LDSST. Forty-two patients underwent ITT.
In this study, Cosyntropin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cosyntropin.
Report a problemFND-1008455801
06HumanNot a test of Cosyntropin aloneNon-randomized trialOther
In patients with pituitary disease, standard-dose tetracosactrin cortisol at 30 min correlated with insulin tolerance test results.
In plain wordsIn patients with pituitary disease, standard-dose tetracosactrin results correlated with insulin tolerance test results.
Peptide
Cosyntropin
Outcome
Not applicableStandard-dose test correlation with insulin tolerance test
Study
n = 42
Comparator
Insulin tolerance test
Outcome group
Diagnostic test performance · Endocrine and hormones
Measurements
Correlation
0.83 r
ITT versus SST
P
< 0.0001
correlation
Source sentences
Summary
the ITT and SST 30 min cortisol levels (r = 0.83; P < 0.0001),
1 context sentence(design, population, supporting numbers)
Summary · context
We studied 64 patients with suspected or proven pituitary disease. All patients underwent SST and LDSST. Forty-two patients underwent ITT.
In this study, Cosyntropin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cosyntropin.
Report a problemFND-1008455802
07HumanNot a test of Cosyntropin aloneNon-randomized trialOther
In patients with pituitary disease, a 600 nmol/L cortisol cutoff was more helpful than 500 nmol/L for both tetracosactrin protocols.
In plain wordsIn patients with pituitary disease, the 600 nmol/L cutoff was more helpful than 500 nmol/L for both tetracosactrin tests.
Peptide
Cosyntropin
Outcome
Not applicableCortisol decision threshold
Study
n: not reported in source
Comparator
500 nmol/L cutoff
Outcome group
Diagnostic test performance · Endocrine and hormones
Measurements
Plasma cortisol cut-off judged more helpful
600 nmol/L
SST 30 min or LDSST peak
Plasma cortisol cut-off compared
500 nmol/L
SST 30 min or LDSST peak
Source sentences
Summary
A plasma cortisol cut-off of 600 nmol/L is more helpful than 500 nmol/L for clinical decision-making using either the SST 30 min cortisol level or the LDSST peak cortisol response.
1 context sentence(design, population, supporting numbers)
Summary · context
We studied 64 patients with suspected or proven pituitary disease. All patients underwent SST and LDSST. Forty-two patients underwent ITT.
In this study, Cosyntropin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cosyntropin.
Report a problemFND-1008455805
08HumanNot a test of Cosyntropin aloneNon-randomized trialOther
In patients with pituitary disease, low-dose tetracosactrin testing had 100% sensitivity at the stated cortisol threshold.
In plain wordsIn patients with pituitary disease, low-dose tetracosactrin testing had 100% sensitivity.
Peptide
Cosyntropin
Outcome
Not applicableLow-dose test sensitivity
Study
n: not reported in source
Outcome group
Diagnostic test performance · Endocrine and hormones
Measurements
Sensitivity
100%
LDSST
Source sentences
Summary
The sensitivity of the LDSST was 100% (cortisol response of >600 nmol/L indicates intact HPA axis), with no falsely reassuring results.
1 context sentence(design, population, supporting numbers)
Summary · context
We studied 64 patients with suspected or proven pituitary disease. All patients underwent SST and LDSST. Forty-two patients underwent ITT.
In this study, Cosyntropin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cosyntropin.
Report a problemFND-1008455806

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:37 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.